Amgen Inc. $AMGN Stake Lowered by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC trimmed its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 3.6% during the second quarter, Holdings Channel reports. The firm owned 401,226 shares of the medical research company’s stock after selling 14,784 shares during the period. Janney Montgomery Scott LLC’s holdings in Amgen were worth $145,292,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Anfield Capital Management LLC increased its position in Amgen by 1,000.0% in the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after buying an additional 70 shares during the period. Dogwood Wealth Management LLC boosted its holdings in shares of Amgen by 275.0% during the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 55 shares during the period. Tower View Wealth Management LLC grew its position in shares of Amgen by 331.6% during the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock worth $29,000 after acquiring an additional 63 shares during the last quarter. Manning & Napier Advisors LLC grew its position in shares of Amgen by 49.2% during the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after acquiring an additional 32 shares during the last quarter. Finally, Ares Financial Consulting LLC acquired a new stake in shares of Amgen in the 4th quarter worth about $34,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $415.21 on Monday. The stock has a market cap of $224.48 billion, a price-to-earnings ratio of 25.81, a PEG ratio of 3.86 and a beta of 0.41. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. Amgen Inc. has a 12 month low of $269.77 and a 12 month high of $421.79. The stock’s 50 day moving average price is $370.57 and its 200 day moving average price is $358.99.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The firm had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. During the same period last year, the company posted $6.02 EPS. The firm’s quarterly revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Equities research analysts anticipate that Amgen Inc. will post 22.78 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be paid a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, August 21st. This represents a $10.08 annualized dividend and a yield of 2.4%. Amgen’s dividend payout ratio (DPR) is currently 62.65%.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 2,970 shares of Amgen stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the transaction, the senior vice president directly owned 7,340 shares of the company’s stock, valued at $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Rachna Khosla sold 2,000 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total transaction of $825,140.00. Following the completion of the sale, the senior vice president owned 6,404 shares in the company, valued at approximately $2,642,098.28. This trade represents a 23.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 6,222 shares of company stock valued at $2,540,926 in the last ninety days. Company insiders own 0.85% of the company’s stock.

Analyst Upgrades and Downgrades

AMGN has been the subject of a number of analyst reports. Sanford C. Bernstein boosted their target price on shares of Amgen from $335.00 to $345.00 and gave the company a “market perform” rating in a research note on Thursday, August 6th. Daiwa Securities Group reduced their price objective on Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a research report on Wednesday, May 13th. BMO Capital Markets raised their target price on Amgen from $400.00 to $450.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. Erste Group Bank reaffirmed a “hold” rating on shares of Amgen in a research note on Tuesday, May 5th. Finally, Truist Financial raised their price target on Amgen from $340.00 to $362.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, fifteen have given a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $372.39.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.